This trial is testing a new medication, Tirosint-SOL, to see if it is better than the current treatment for Congenital Hypothyroidism.
6 Primary · 4 Secondary · Reporting Duration: Up to 22 months based on age group
Active Control
Experimental Treatment
126 Total Participants · 2 Treatment Groups
Primary Treatment: Tirosint®-SOL · No Placebo Group · Phase 4
Age 1 - 9 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: